Genelux Corporation (GNLX)

Genelux will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$6.00 - $7.00
Shares Offered
2,500,000
Deal Size
$16.25M

Company Description

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.

We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer in the second quarter of 2022.

Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.

These provide potential utility in multiple tumor types in both the monotherapy and combination therapy settings, via physician-preferred administration techniques, including regional (e.g., intraperitoneal) and systemic (e.g., intravenous) delivery routes.

Informed by our CHOICE platform and supported by extensive clinical and preclinical data, we believe we have the capacity to develop a pipeline of treatment options to address high unmet medical needs for those patients with insignificant or unsatisfactory responses to standard-of-care therapies, including chemotherapies.

From this library, we selected Olvi-Vec, which we believe has the potential to exhibit anti-tumor properties, including potent oncolytic properties (tumor cell lysis) and to activate both the innate and adaptive arms of the immune system, to produce favorable changes within the tumor microenvironment.

The personalized and multi-modal immune activation generated by Olvi-Vec is designed with the goal to yield clinically-meaningful anti-tumor responses to virus treatment alone and in combination with other existing treatment modalities.

Genelux Corporation
Country United States
Founded 2001
Industry Health Care
Sector Biotechnology
Employees 14
CEO Thomas Zindrick, J.D.

Contact Details

Address:
2625 Townsgate Road, Suite 230
Westlake Village, CA 91361
United States
Phone (805) 267-9889
Website genelux.com

Stock Details

Ticker Symbol GNLX
Exchange NASDAQ
Reporting Currency USD
CIK Code 0001231457
SIC Code 2834

Key Executives

Name Position
Thomas Zindrick, J.D. President, Chief Executive Officer and Chairman
Paul Scigalla, M.D., Ph.D. Chief Medical Officer
Tony Yu, Ph.D. Vice President, Clinical Trial Operations
Joseph Cappello, Ph.D. Vice President, Pharmaceutical Development and General Manager of Manufacturing
Qian Zhang Associate Vice President, Research
Sean Ryder General Counsel and Corporate Secretary
Mary Mirabelli Director
John Thomas, Ph.D. Director
James L. Tyree Lead Independent Director
Gabe Woodward Director

Latest SEC Filings

Date Type Title
Nov 4, 2022 FWP Free Writing Prospectus
Nov 4, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 13, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Oct 4, 2022 FWP Free Writing Prospectus
Sep 19, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Aug 29, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 24, 2022 S-1 General form for registration of securities under the Securities Act of 1933
May 20, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
Jun 24, 2021 DRS/A [Amend] [Cover] Draft Registration Statement
May 7, 2021 DRS [Cover] Draft Registration Statement